Johnson & Johnson (JNJ) operating KPIs
JNJNYSEPharmaceutical PreparationsFiscal year ends January 3
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Oct 21, 2026Score 12/3043% above fair value
$273.20−2.00 (-0.73%)
Close on Oct 30, 2026Market cap $658.38BP/E 31.7Yield 1.88%
Johnson & Johnson over-the-Counter (OTC) Medicines (TYLENOL, MOTRIN, ZYRTEC) — Worldwide sales ($M) ($M)
Form 10-Q / 10-K Segment Note & Form 8-K EX-99.2 Segment Sales Schedule
Latest, Q2 2023
1,659
Period ended Jul 2, 2023
Change on a year earlier
+11.9%
1,482 in Q2 2022
History
27 quarters
Since Q4 2016
Sources
19
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Over-the-Counter (OTC) Medicines (TYLENOL, MOTRIN, ZYRTEC) — Worldwide sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2023 | Jul 2, 2023 | 1,659 | +11.9% | Form 10-Q (filed 2023-07-31) ↗ |
| Q1 2023 | Apr 2, 2023 | 1,642 | +12.4% | Form 10-Q (filed 2023-04-28) ↗ |
| Q4 2022 | Jan 1, 2023 | 1,569 | +8.7% | Form 10-K (filed 2023-02-16) ↗ |
| Q3 2022 | Oct 2, 2022 | 1,519 | +2.4% | Form 10-Q (filed 2022-10-27) ↗ |
| Q2 2022 | Jul 3, 2022 | 1,482 | +3.9% | Form 10-Q (filed 2023-07-31) ↗ |
| Q1 2022 | Apr 3, 2022 | 1,461 | +14.8% | Form 10-Q (filed 2023-04-28) ↗ |
| Q4 2021 | Jan 2, 2022 | 1,444 | -8.7% | Form 10-K (filed 2023-02-16) ↗ |
| Q3 2021 | Oct 3, 2021 | 1,484 | +29.9% | Form 10-Q (filed 2022-10-27) ↗ |
| Q2 2021 | Jul 4, 2021 | 1,426 | +24.1% | Form 10-Q (filed 2022-07-29) ↗ |
| Q1 2021 | Apr 4, 2021 | 1,273 | -5.6% | Form 10-Q (filed 2022-04-29) ↗ |
| Q4 2020 | Jan 3, 2021 | 1,582 | +32.4% | Form 10-K (filed 2023-02-16) ↗ |
| Q3 2020 | Sep 27, 2020 | 1,142 | +4.0% | Form 10-Q (filed 2021-10-29) ↗ |
| Q2 2020 | Jun 28, 2020 | 1,149 | -4.4% | Form 10-Q (filed 2021-07-29) ↗ |
| Q1 2020 | Mar 29, 2020 | 1,348 | +24.0% | Form 10-Q (filed 2021-04-30) ↗ |
| Q4 2019 | Dec 29, 2019 | 1,195 | +4.1% | Form 10-K (filed 2022-02-17) ↗ |
| Q3 2019 | Sep 29, 2019 | 1,098 | +4.8% | Form 10-Q (filed 2020-10-23) ↗ |
| Q2 2019 | Jun 30, 2019 | 1,202 | +12.8% | Form 10-Q (filed 2020-07-24) ↗ |
| Q1 2019 | Mar 31, 2019 | 1,087 | +1.4% | Form 10-Q (filed 2019-05-01) ↗ |
| Q4 2018 | Dec 30, 2018 | 1,148 | +3.9% | Form 10-K (filed 2021-02-22) ↗ |
| Q3 2018 | Sep 30, 2018 | 1,048 | +4.6% | Form 10-Q (filed 2018-10-31) ↗ |
| Q2 2018 | Jul 1, 2018 | 1,066 | +6.0% | Form 10-Q (filed 2018-08-02) ↗ |
| Q1 2018 | Apr 1, 2018 | 1,072 | +5.8% | Form 10-Q (filed 2019-05-01) ↗ |
| Q4 2017 | Dec 31, 2017 | 1,105 | +6.4% | Form 10-K (filed 2019-02-20) ↗ |
| Q3 2017 | Oct 1, 2017 | 1,002 | – | Form 10-Q (filed 2018-10-31) ↗ |
| Q2 2017 | Jul 2, 2017 | 1,006 | – | Form 10-Q (filed 2018-08-02) ↗ |
| Q1 2017 | Apr 2, 2017 | 1,013 | – | Form 10-Q (filed 2018-05-01) ↗ |
| Q4 2016 | Jan 1, 2017 | 1,039 | – | Form 8-K (a8k2017q4exhibit9915.htm, filed 2018-01-23) ↗ |
Breakdown
What makes up over-the-counter (otc) medicines (tylenol, motrin, zyrtec) — worldwide sales ($m)
- Over-the-Counter (OTC) Medicines (TYLENOL, MOTRIN, ZYRTEC) — U.S. sales ($M)712 · Q2 2023
- Over-the-Counter (OTC) Medicines (TYLENOL, MOTRIN, ZYRTEC) — International sales ($M)947 · Q2 2023
- Over-the-Counter (OTC) Medicines (TYLENOL, MOTRIN, ZYRTEC) — Worldwide reported growth YoY (%)12.0% · Q2 2023
- Over-the-Counter (OTC) Medicines (TYLENOL, MOTRIN, ZYRTEC) — Worldwide operational (constant-currency) growth YoY (%)13.9% · Q2 2023
Cite this data
StockData. (2026). Johnson & Johnson Over-the-Counter (OTC) Medicines (TYLENOL, MOTRIN, ZYRTEC) — Worldwide sales ($M) ($M), quarterly Q4 2016–Q2 2023 [Data set]. Compiled from Johnson & Johnson SEC filings and investor materials. https://stockdatahq.com/stocks/jnj/kpis/ch_otc
See every metric in the Johnson & Johnson KPI table. Data updated Oct 25, 2026.